Scarica l'app Stockscreener
1.32
5.60%
0.07
Pre-mercato:
1.29
-0.03
-2.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.25
Aprire:
$1.26
Volume 24 ore:
2.00M
Relative Volume:
0.60
Capitalizzazione di mercato:
$172.21M
Reddito:
-
Utile/perdita netta:
$-97.17M
Rapporto P/E:
-1.7683
EPS:
-0.7465
Flusso di cassa netto:
$-85.97M
1 W Prestazione:
+14.78%
1M Prestazione:
+44.99%
6M Prestazione:
+46.94%
1 anno Prestazione:
+5.60%
Intervallo 1D:
$1.26
$1.35
Intervallo di 1 settimana:
$1.07
$1.35
Portata 52W:
$0.5062
$1.51
Immunic Inc Stock (IMUX) Company Profile
Nome
Immunic Inc
Settore
Industria
Telefono
(332) 255-9818
Indirizzo
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.32 | 172.21M | 0 | -97.17M | -85.97M | -0.7465 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Iniziato | Roth Capital | Buy |
| 2025-09-29 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-25 | Iniziato | William Blair | Outperform |
| 2024-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-27 | Iniziato | B. Riley Securities | Buy |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2021-04-15 | Iniziato | Aegis Capital | Buy |
| 2021-03-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-08-07 | Ripresa | ROTH Capital | Buy |
| 2020-07-20 | Iniziato | BMO Capital Markets | Outperform |
| 2020-06-05 | Iniziato | Wedbush | Outperform |
| 2020-05-11 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-25 | Iniziato | ROTH Capital | Buy |
| 2019-07-11 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Immunic Inc Borsa (IMUX) Ultime notizie
IMUX SEC FilingsImmunic Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim initiates coverage of Immunic (IMUX) with buy recommendation - MSN
If You Invested $1,000 in Immunic Inc (IMUX) - Stock Titan
Immunic stock jumps after Guggenheim initiates with Buy By Investing.com - Investing.com Canada
Immunic (IMUX) Gains on Guggenheim's Buy Rating and Promising Drug Potential - GuruFocus
Immunic stock jumps after Guggenheim initiates with Buy - Investing.com UK
Immunic stock gains new Buy at Guggenheim (IMUX:NASDAQ) - Seeking Alpha
Immunic (NASDAQ:IMUX) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
IMUX: Guggenheim Initiates Coverage with a Buy Rating and $7 Pri - GuruFocus
Immunic stock initiated at Buy by Guggenheim on MS therapy potential By Investing.com - Investing.com South Africa
Immunic stock initiated at Buy by Guggenheim on MS therapy potential - Investing.com
Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Tangible book value per share of Immunic, Inc. – FWB:10VA - TradingView
Bull Bear: Does Immunic Inc meet Warren Buffetts criteria2026 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn
US Stocks Recap: Will Immunic Inc stock recover after earningsFed Meeting & Weekly Return Optimization Alerts - baoquankhu1.vn
Immunic, Inc. (IMUX) announces European patent grant for vidofludimus calcium - MSN
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium - Insider Monkey
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next - MarketBeat
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug By Investing.com - Investing.com Canada
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug - Investing.com
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference - MarketBeat
Immunic Inc Stock Operating Data - GuruFocus
Why did IMUX stock surge 33% pre-market today? - MSN
Short Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 14.5% - MarketBeat
Immunic Stock Under Pressure Amid Financial Changes and Market Reactions - StocksToTrade
Immunic Shares Rise Amid Resilient Strategy In Uncertain Markets - timothysykes.com
Immunic Inc. Faces Slow Recovery Amid Financial Struggles - StocksToTrade
symbol__ Stock Quote Price and Forecast - CNN
Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic’s (IMUX) Long-Term Value Proposition? - simplywall.st
New European patent covers all dosing regimens of experimental MS therapy - Multiple Sclerosis News Today
A Look At Immunic (IMUX) Valuation As Reverse Split Proposal And Conference Appearance Draw Attention - simplywall.st
Volume Recap: What makes Immunic Inc stock attractive today2026 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug - Investing.com Australia
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug By Investing.com - Investing.com India
Immunic secures European patent for vidofludimus calcium dosing By Investing.com - Investing.com Canada
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
Immunic secures European patent for vidofludimus calcium dosing - Investing.com Nigeria
Immunic (IMUX) Secures Key European Patent for Vidofludimus Calc - GuruFocus
Biopharmaceutical company Immunic, Inc. announced that it has been granted a key European patent, which will provide important protection for the administration regimen related to Vidofludimus calcium. - Bitget
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PR Newswire
Immunic secures European patent for MS drug candidate vidofludimus calcium - Proactive financial news
What makes Immunic Inc. (10VA) stock appealing to growth investorsOil Prices & Real-Time Volume Surge Alerts - Naître et grandir
IMUX Forecast, Price Target & Analyst Ratings | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
IMUX Earnings History & Surprises | EPS & Revenue Results | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Stocktwits
Earnings Update: Whats the analyst consensus on Immunic IncDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
HC Wainwright Has Bearish Estimate for Immunic Q1 Earnings - MarketBeat
Deep Track group reports 11.45M-share stake in Immunic (IMUX) - Stock Titan
Immunic Inc Azioni (IMUX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):